Catalyst
Slingshot members are tracking this event:
Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer Final Data Expected October 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PBYI | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 13, 2017
Occurred Source:
http://www.pumabiotechnology.com/pr20171113.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Trastuzumab Emtansine, Neratinib, Metastatic Her2-positive Breast Cancer, Kadcyla
